Darlene Deptula-Hicks has served on the board of directors and as audit committee chair of Abcuro since July 2021. Darlene joined Aerami Therapeutics as Chief Financial Officer in October 2023, where she has been on the board of directors and chair of the audit committee since October 2021. Prior to Aerami, Darlene most recently served as Chief Financial Officer of F-star Therapeutics (FSTX) since 2019, which she took public in 2020 and through to the successful sale of the Company in March 2023. In addition, since early 2018 Darlene has operated Crimson Consulting, LLC, a strategic, financial and CFO consulting services company, and has also served as acting Chief Financial Officer for Northern Biologics from 2018 and to the successful sale of its preclinical and clinical programs to Boehringer Ingelheim and Astra Zeneca in 2020. Prior, she was the Senior Vice President and Chief Financial Officer of T2 Biosystems (TTOO). Previously she was Senior Vice President and Chief Financial Officer of Pieris Pharmaceuticals (PIRS) which she also took public and Vice President and Chief Financial Officer of Microline Surgical. Darlene currently serves on the board of directors of Aerami Therapeutics and previously served on the board of directors and as audit committee chair of Giner Life Sciences, Xentic Biosciences, and IMCOR Pharmaceuticals. Darlene received her M.B.A. from Rivier University and a B.S in Accounting from Southern New Hampshire University.
Deptula-Hicks, Darlene
Darlene Deptula-Hicks
Board of Directors & Audit Committee Chair
x
Darlene Deptula-Hicks
Board of Directors & Audit Committee Chair
Darlene Deptula-Hicks has served on the board of directors and as audit committee chair of Abcuro since July 2021. Darlene joined Aerami Therapeutics as Chief Financial Officer in October 2023, where she has been on the board of directors and chair of the audit committee since October 2021. Prior to Aerami, Darlene most recently served as Chief Financial Officer of F-star Therapeutics (FSTX) since 2019, which she took public in 2020 and through to the successful sale of the Company in March 2023. In addition, since early 2018 Darlene has operated Crimson Consulting, LLC, a strategic, financial and CFO consulting services company, and has also served as acting Chief Financial Officer for Northern Biologics from 2018 and to the successful sale of its preclinical and clinical programs to Boehringer Ingelheim and Astra Zeneca in 2020. Prior, she was the Senior Vice President and Chief Financial Officer of T2 Biosystems (TTOO). Previously she was Senior Vice President and Chief Financial Officer of Pieris Pharmaceuticals (PIRS) which she also took public and Vice President and Chief Financial Officer of Microline Surgical. Darlene currently serves on the board of directors of Aerami Therapeutics and previously served on the board of directors and as audit committee chair of Giner Life Sciences, Xentic Biosciences, and IMCOR Pharmaceuticals. Darlene received her M.B.A. from Rivier University and a B.S in Accounting from Southern New Hampshire University.
